Pharmacologic therapeutics for cardiac reperfusion injury.
about
The reno-vascular A2B adenosine receptor protects the kidney from ischemiaMitochondrial KATP channel inhibition blunts arrhythmia protection in ischemic exercised hearts.Myocardial matrix metalloproteinase-2: inside out and upside down.Adenosine relaxation in isolated rat aortic rings and possible roles of smooth muscle Kv channels, KATP channels and A2a receptorsAcute and chronic cardioprotection by the enkephalin analogue, Eribis peptide 94, is mediated via activation of nitric oxide synthase and adenosine triphosphate-regulated potassium channelsACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease.Exercise and cardiac preconditioning against ischemia reperfusion injury.Ischemic Preconditioning And Myocardial Infarction: An Update and Perspective.JAK redux: a second look at the regulation and role of JAKs in the heart.Intracellular regulation of matrix metalloproteinase-2 activity: new strategies in treatment and protection of heart subjected to oxidative stressLidocaine relaxation in isolated rat aortic rings is enhanced by endothelial removal: possible role of Kv, KATP channels and A2a receptor crosstalk.In vivo models of cardiac diseases: application to drug development and screening.Pharmacological attenuation of myocardial reperfusion injury in a closed-chest porcine model: a systematic review.Combined subthreshold dose inhibition of myosin light chain phosphorylation and MMP-2 activity provides cardioprotection from ischaemic/reperfusion injury in isolated rat heart.Protective effect of hydroalcoholic extract of Andrographis paniculata on ischaemia-reperfusion induced myocardial injury in rats.Positive feedback in cardioprotection: can more mechanism lead to translation?
P2860
Q28473410-A95690CB-C214-427C-A312-13553C298226Q33994857-1813CE3E-0E74-4952-A06F-C936354584F9Q35032465-BCAC20BE-F6D0-402C-813C-739FADAB1845Q36025879-74028470-6216-4661-B53A-5281E97E6B43Q36350926-BD35CDE7-6BB7-4BF2-8C1C-2B27D585854DQ36726341-8D03165F-1D52-475A-9FF8-A0316CA3F80CQ37190421-155B0FEF-A3AD-45A1-962B-070DF2DF8B13Q37243210-74EC7D1A-CE0A-4927-B820-1DB3AC28C6FAQ37430884-A19C9A4C-113D-4209-9C70-8B05B7922E50Q37456901-2D061535-928A-4483-BA86-A941C9F1B6F4Q37470421-96873128-DD3F-4DB8-830F-E4ABE320FD83Q38028652-B43D76E6-3266-48AF-BBB7-BB95A1DD81F9Q38227381-5A872793-5AF0-4A5A-9B41-CBFD820692F5Q42058629-EB5C57BE-83CC-4237-9AAA-11CDE70C6D8FQ42179427-4ADBD8C1-4A28-45BA-BA49-1593F328E793Q42724342-391D3452-02E9-4A5B-AEF2-E6077F25199E
P2860
Pharmacologic therapeutics for cardiac reperfusion injury.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacologic therapeutics for cardiac reperfusion injury.
@en
type
label
Pharmacologic therapeutics for cardiac reperfusion injury.
@en
prefLabel
Pharmacologic therapeutics for cardiac reperfusion injury.
@en
P2860
P1476
Pharmacologic therapeutics for cardiac reperfusion injury.
@en
P2093
Eric R Gross
Garrett J Gross
P2860
P304
P356
10.1517/14728214.12.3.367
P407
P577
2007-09-01T00:00:00Z